We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)

News   Sep 27, 2012

 
CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)
 
 
 

RELATED ARTICLES

Ebola Patients Have a 90% Survival Rate After Injection With New Drugs

News

Two Ebola drugs have proven so effective in a clinical trial that researchers will make the treatments available to anyone infected with the virus in the Democratic Republic of the Congo, where Ebola has killed nearly 1,900 people over the past year.

READ MORE

Drug Targets Early Instigator of Alzheimer's Disease

News

Therapeutic efforts to target "plaques and tangles", considered classic hallmarks of Alzheimer's disease, have previously met with dispiriting failure. Now researchers are exploring a drug called "DYR219" – its strength lies in the fact that it can target both plaques and tangles.

READ MORE

Drug Could Speed Up Blood System’s Recovery After Chemo, Suggests Mouse Study

News

A drug has been developed that speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If these results can be replicated in humans, the compound known as "DJ009" could help people recover quicker from chemotherapy, radiation and bone marrow transplants.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE